ArticleTranslational lung cancer research2026
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse cystic lung disease (DCLD) in women of reproductive age is often attributed to lymphangioleiomyomatosis (LAM), but malignancy should be considered when atypical features are present. Case Description: We report the case of a 27-year-old never-smoking woman initially diagnosed with LAM based on high-resolution computed tomography (HRCT) findings, who was subsequently found to have metastatic lung adenocarcinoma on supraclavicular lymph node biopsy. Her first HRCT showed diffuse thin-walled lung cysts, and in 6 months, the second HRCT showed diffuse cysts (2-14 mm) with heterogeneous cyst-wall thickness plus a left upper-lobe patchy opacity, as well as beaded pleural-based fissural nodules in the right lung. Meanwhile, her serum carcinoembryonic antigen (CEA) was 21.96 ng/mL and the supraclavicular node biopsy confirmed metastatic lung adenocarcinoma (cT4N3M1a, stage IVA). DNA-based next-generation sequencing (NGS) identified an Conclusions: In a LAM-like cystic background, the presence of superimposed focal opacities or nodules, fissural beading, and heterogeneous cyst-wall thickness should prompt an expedited malignancy work-up rather than an HRCT-only diagnosis, as this case demonstrates that systematic evaluation of atypical features in presumed LAM can identify treatable oncogene-driven malignancies amenable to highly effective targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.